ADC Therapeutics SA (ADCT) Q4 2025 Earnings Call Transcript

Why It Matters

The financing secures development capital while clinical progress positions ZENLATA to capture a larger share of the lucrative DLBCL and indolent lymphoma markets.

Key Takeaways

• Net product revenue fell to $15.8M, down YoY.
• GAAP net loss narrowed to $41M, $0.30 per share.
• $60M PIPE extends cash runway to 2028.
• ZENLATA shows 98% ORR in follicular lymphoma trial.
• LOTUS V/VII data 2026‑2027 could boost revenue.

Pulse Analysis

ADC Therapeutics’ latest quarter underscores a classic biotech trade‑off: modest revenue contraction offset by disciplined cost management and a robust cash cushion. Revenue slipped as ordering patterns remained volatile, yet the company trimmed non‑GAAP operating expenses by over 12%, primarily through reduced R&D outlays. The $60 million private placement not only replenishes the balance sheet but also signals investor confidence, granting the firm a runway that comfortably reaches 2028 and allowing continued investment in its pipeline without immediate dilution concerns.

Clinically, ZENLATA continues to generate compelling data across multiple indications. In a follicular lymphoma investigator‑initiated trial, the antibody‑drug conjugate achieved a 98.2% overall response rate and an 83.6% complete response rate, with 12‑month progression‑free survival nearing 94% and no new safety signals. These results reinforce ZENLATA’s efficacy profile and lay groundwork for regulatory and compendia submissions. Meanwhile, the Phase III LOTUS V trial (ZENLATA + rituximab) and the Phase Ib LOTUS VII study (ZENLATA + glofitamab) are on accelerated enrollment paths, with top‑line data expected in 2026 and 2027 respectively, milestones that could dramatically expand the drug’s addressable market.

From a market perspective, ADC Therapeutics is targeting a $600 million‑$1 billion peak revenue opportunity by moving ZENLATA into earlier lines of diffuse large B‑cell lymphoma (DLBCL) and indolent lymphomas. Successful outcomes from LOTUS V and VII would not only double the patient pool but also position ZENLATA as a versatile, broadly accessible therapy alongside complex modalities like CAR‑T. Investors should watch the upcoming data releases, as positive readouts could trigger significant valuation uplift and solidify the company’s foothold in a competitive oncology landscape.